Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tevogen Bio Holdings Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TVGN
Nasdaq
8731
https://www.semperparatusspac.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tevogen Bio Holdings Inc
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
- May 1st, 2024 12:05 pm
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
- Apr 26th, 2024 1:23 pm
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
- Apr 11th, 2024 12:05 pm
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
- Apr 3rd, 2024 12:05 pm
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
- Mar 28th, 2024 12:05 pm
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
- Mar 20th, 2024 11:00 am
Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita
- Mar 5th, 2024 1:00 pm
With a 86% stake, Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insiders have a lot riding on the company
- Feb 29th, 2024 12:42 pm
Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI
- Feb 27th, 2024 9:39 pm
Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment
- Feb 21st, 2024 12:00 pm
Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market
- Feb 17th, 2024 5:17 am
Tevogen Bio Announces $8 Million Equity Investment
- Feb 15th, 2024 2:25 pm
Tevogen Bio Introduces Tevogen.ai to Enhance Patient Accessibility and Accelerate Innovation Leveraging Artificial Intelligence
- Oct 10th, 2023 8:35 pm
Scroll